CN1282463C - 一种具有平肝活血安神作用的中药组合物、制备方法和应用 - Google Patents
一种具有平肝活血安神作用的中药组合物、制备方法和应用 Download PDFInfo
- Publication number
- CN1282463C CN1282463C CN 200410016412 CN200410016412A CN1282463C CN 1282463 C CN1282463 C CN 1282463C CN 200410016412 CN200410016412 CN 200410016412 CN 200410016412 A CN200410016412 A CN 200410016412A CN 1282463 C CN1282463 C CN 1282463C
- Authority
- CN
- China
- Prior art keywords
- extract
- group
- caulis
- arachidis hypogaeae
- chinese medicine
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 65
- 238000002360 preparation method Methods 0.000 title claims abstract description 23
- 210000004185 liver Anatomy 0.000 title claims abstract description 21
- 230000001914 calming effect Effects 0.000 title abstract description 19
- 230000017531 blood circulation Effects 0.000 title abstract description 5
- 230000001737 promoting effect Effects 0.000 title description 3
- 239000003814 drug Substances 0.000 claims abstract description 88
- 230000000694 effects Effects 0.000 claims abstract description 51
- 208000013738 Sleep Initiation and Maintenance disease Diseases 0.000 claims abstract description 27
- 206010022437 insomnia Diseases 0.000 claims abstract description 25
- 238000009472 formulation Methods 0.000 claims abstract description 14
- 239000000546 pharmaceutical excipient Substances 0.000 claims abstract description 6
- 229940079593 drug Drugs 0.000 claims description 46
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 32
- 238000000034 method Methods 0.000 claims description 29
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 20
- 239000007788 liquid Substances 0.000 claims description 17
- 239000000706 filtrate Substances 0.000 claims description 12
- PAFLSMZLRSPALU-MRVPVSSYSA-N (2R)-3-(3,4-dihydroxyphenyl)lactic acid Chemical compound OC(=O)[C@H](O)CC1=CC=C(O)C(O)=C1 PAFLSMZLRSPALU-MRVPVSSYSA-N 0.000 claims description 7
- FMIPNAUMSPFTHK-AKGZTFGVSA-N (2s)-4-hydroxy-1-methylpyrrolidine-2-carboxylic acid Chemical compound CN1CC(O)C[C@H]1C(O)=O FMIPNAUMSPFTHK-AKGZTFGVSA-N 0.000 claims description 7
- PAFLSMZLRSPALU-QMMMGPOBSA-N Danshensu Natural products OC(=O)[C@@H](O)CC1=CC=C(O)C(O)=C1 PAFLSMZLRSPALU-QMMMGPOBSA-N 0.000 claims description 7
- FMIPNAUMSPFTHK-UHFFFAOYSA-N Hydroxyhygrinic acid Natural products CN1CC(O)CC1C(O)=O FMIPNAUMSPFTHK-UHFFFAOYSA-N 0.000 claims description 7
- PAFLSMZLRSPALU-UHFFFAOYSA-N Salvianic acid A Natural products OC(=O)C(O)CC1=CC=C(O)C(O)=C1 PAFLSMZLRSPALU-UHFFFAOYSA-N 0.000 claims description 7
- 238000004321 preservation Methods 0.000 claims description 5
- 239000004480 active ingredient Substances 0.000 claims description 4
- 239000008187 granular material Substances 0.000 claims description 4
- 238000004128 high performance liquid chromatography Methods 0.000 claims description 4
- 239000012567 medical material Substances 0.000 claims description 4
- 238000001556 precipitation Methods 0.000 claims description 4
- 239000006187 pill Substances 0.000 claims description 3
- 239000002775 capsule Substances 0.000 claims description 2
- 238000007796 conventional method Methods 0.000 claims description 2
- 235000008216 herbs Nutrition 0.000 claims description 2
- 239000003826 tablet Substances 0.000 claims description 2
- 238000000605 extraction Methods 0.000 claims 1
- 210000005036 nerve Anatomy 0.000 abstract description 30
- 240000007164 Salvia officinalis Species 0.000 abstract description 3
- 235000005412 red sage Nutrition 0.000 abstract description 3
- 235000017060 Arachis glabrata Nutrition 0.000 abstract 2
- 244000105624 Arachis hypogaea Species 0.000 abstract 2
- 235000010777 Arachis hypogaea Nutrition 0.000 abstract 2
- 235000018262 Arachis monticola Nutrition 0.000 abstract 2
- 230000003213 activating effect Effects 0.000 abstract 2
- 235000020232 peanut Nutrition 0.000 abstract 2
- 239000002131 composite material Substances 0.000 abstract 1
- 241000699670 Mus sp. Species 0.000 description 30
- 230000007958 sleep Effects 0.000 description 29
- 241001465754 Metazoa Species 0.000 description 20
- 241000700159 Rattus Species 0.000 description 19
- 210000002784 stomach Anatomy 0.000 description 18
- 239000008188 pellet Substances 0.000 description 11
- 238000011084 recovery Methods 0.000 description 10
- 230000004622 sleep time Effects 0.000 description 10
- QGMRQYFBGABWDR-UHFFFAOYSA-M Pentobarbital sodium Chemical compound [Na+].CCCC(C)C1(CC)C(=O)NC(=O)[N-]C1=O QGMRQYFBGABWDR-UHFFFAOYSA-M 0.000 description 9
- 150000001875 compounds Chemical class 0.000 description 9
- 229960002275 pentobarbital sodium Drugs 0.000 description 9
- 230000002567 autonomic effect Effects 0.000 description 8
- 210000004369 blood Anatomy 0.000 description 8
- 239000008280 blood Substances 0.000 description 8
- 238000002474 experimental method Methods 0.000 description 8
- 238000004458 analytical method Methods 0.000 description 7
- 239000012153 distilled water Substances 0.000 description 7
- 238000011156 evaluation Methods 0.000 description 7
- 238000011160 research Methods 0.000 description 7
- 210000000582 semen Anatomy 0.000 description 7
- 208000032843 Hemorrhage Diseases 0.000 description 6
- 208000002173 dizziness Diseases 0.000 description 6
- 210000002216 heart Anatomy 0.000 description 6
- 238000009413 insulation Methods 0.000 description 6
- 230000000144 pharmacologic effect Effects 0.000 description 6
- 238000012360 testing method Methods 0.000 description 6
- 230000001225 therapeutic effect Effects 0.000 description 6
- 210000004556 brain Anatomy 0.000 description 5
- 230000003203 everyday effect Effects 0.000 description 5
- 210000004072 lung Anatomy 0.000 description 5
- 208000011580 syndromic disease Diseases 0.000 description 5
- 241000699666 Mus <mouse, genus> Species 0.000 description 4
- 238000003556 assay Methods 0.000 description 4
- 230000037396 body weight Effects 0.000 description 4
- 230000008859 change Effects 0.000 description 4
- 230000000052 comparative effect Effects 0.000 description 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 4
- 238000011049 filling Methods 0.000 description 4
- 238000002347 injection Methods 0.000 description 4
- 239000007924 injection Substances 0.000 description 4
- 235000012054 meals Nutrition 0.000 description 4
- 239000013641 positive control Substances 0.000 description 4
- 230000002618 waking effect Effects 0.000 description 4
- 208000007271 Substance Withdrawal Syndrome Diseases 0.000 description 3
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 3
- 229930006000 Sucrose Natural products 0.000 description 3
- 238000006243 chemical reaction Methods 0.000 description 3
- 230000007812 deficiency Effects 0.000 description 3
- AAOVKJBEBIDNHE-UHFFFAOYSA-N diazepam Chemical compound N=1CC(=O)N(C)C2=CC=C(Cl)C=C2C=1C1=CC=CC=C1 AAOVKJBEBIDNHE-UHFFFAOYSA-N 0.000 description 3
- 229960003529 diazepam Drugs 0.000 description 3
- 238000001914 filtration Methods 0.000 description 3
- 239000012530 fluid Substances 0.000 description 3
- 230000002496 gastric effect Effects 0.000 description 3
- 238000001802 infusion Methods 0.000 description 3
- 210000003734 kidney Anatomy 0.000 description 3
- 230000005622 photoelectricity Effects 0.000 description 3
- 238000012216 screening Methods 0.000 description 3
- 239000000243 solution Substances 0.000 description 3
- 230000008925 spontaneous activity Effects 0.000 description 3
- 239000005720 sucrose Substances 0.000 description 3
- 231100000419 toxicity Toxicity 0.000 description 3
- 230000001988 toxicity Effects 0.000 description 3
- 208000024172 Cardiovascular disease Diseases 0.000 description 2
- 206010037660 Pyrexia Diseases 0.000 description 2
- 208000032023 Signs and Symptoms Diseases 0.000 description 2
- 208000032851 Subarachnoid Hemorrhage Diseases 0.000 description 2
- 230000000903 blocking effect Effects 0.000 description 2
- 239000012141 concentrate Substances 0.000 description 2
- 229940109275 cyclamate Drugs 0.000 description 2
- HCAJEUSONLESMK-UHFFFAOYSA-N cyclohexylsulfamic acid Chemical compound OS(=O)(=O)NC1CCCCC1 HCAJEUSONLESMK-UHFFFAOYSA-N 0.000 description 2
- 230000004069 differentiation Effects 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 230000000857 drug effect Effects 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 210000003743 erythrocyte Anatomy 0.000 description 2
- 230000000147 hypnotic effect Effects 0.000 description 2
- 238000002386 leaching Methods 0.000 description 2
- 238000002156 mixing Methods 0.000 description 2
- 210000004165 myocardium Anatomy 0.000 description 2
- 210000000056 organ Anatomy 0.000 description 2
- 230000007170 pathology Effects 0.000 description 2
- 238000012545 processing Methods 0.000 description 2
- 230000000630 rising effect Effects 0.000 description 2
- 230000004799 sedative–hypnotic effect Effects 0.000 description 2
- 230000011218 segmentation Effects 0.000 description 2
- 208000019116 sleep disease Diseases 0.000 description 2
- 230000003860 sleep quality Effects 0.000 description 2
- 208000020685 sleep-wake disease Diseases 0.000 description 2
- WXMKPNITSTVMEF-UHFFFAOYSA-M sodium benzoate Chemical compound [Na+].[O-]C(=O)C1=CC=CC=C1 WXMKPNITSTVMEF-UHFFFAOYSA-M 0.000 description 2
- 235000010234 sodium benzoate Nutrition 0.000 description 2
- 239000004299 sodium benzoate Substances 0.000 description 2
- 230000002269 spontaneous effect Effects 0.000 description 2
- 210000002330 subarachnoid space Anatomy 0.000 description 2
- 239000006228 supernatant Substances 0.000 description 2
- 210000001541 thymus gland Anatomy 0.000 description 2
- 230000003442 weekly effect Effects 0.000 description 2
- WTPPRJKFRFIQKT-UHFFFAOYSA-N 1,6-dimethyl-8,9-dihydronaphtho[1,2-g][1]benzofuran-10,11-dione;1-methyl-6-methylidene-8,9-dihydro-7h-naphtho[1,2-g][1]benzofuran-10,11-dione Chemical compound O=C1C(=O)C2=C3CCCC(=C)C3=CC=C2C2=C1C(C)=CO2.O=C1C(=O)C2=C3CCC=C(C)C3=CC=C2C2=C1C(C)=CO2 WTPPRJKFRFIQKT-UHFFFAOYSA-N 0.000 description 1
- 238000001644 13C nuclear magnetic resonance spectroscopy Methods 0.000 description 1
- 240000007185 Albizia julibrissin Species 0.000 description 1
- 235000011468 Albizia julibrissin Nutrition 0.000 description 1
- 206010003084 Areflexia Diseases 0.000 description 1
- 206010065559 Cerebral arteriosclerosis Diseases 0.000 description 1
- 206010008909 Chronic Hepatitis Diseases 0.000 description 1
- 206010053567 Coagulopathies Diseases 0.000 description 1
- 239000004375 Dextrin Substances 0.000 description 1
- 229920001353 Dextrin Polymers 0.000 description 1
- 208000007882 Gastritis Diseases 0.000 description 1
- 206010020772 Hypertension Diseases 0.000 description 1
- 240000002836 Ipomoea tricolor Species 0.000 description 1
- 238000012449 Kunming mouse Methods 0.000 description 1
- 238000005481 NMR spectroscopy Methods 0.000 description 1
- 102100026459 POU domain, class 3, transcription factor 2 Human genes 0.000 description 1
- 101710133394 POU domain, class 3, transcription factor 2 Proteins 0.000 description 1
- 206010033557 Palpitations Diseases 0.000 description 1
- 244000131316 Panax pseudoginseng Species 0.000 description 1
- 235000005035 Panax pseudoginseng ssp. pseudoginseng Nutrition 0.000 description 1
- 235000003140 Panax quinquefolius Nutrition 0.000 description 1
- 206010035664 Pneumonia Diseases 0.000 description 1
- 208000035992 Postmortem Changes Diseases 0.000 description 1
- 206010037394 Pulmonary haemorrhage Diseases 0.000 description 1
- 206010039897 Sedation Diseases 0.000 description 1
- 208000007536 Thrombosis Diseases 0.000 description 1
- 244000126002 Ziziphus vulgaris Species 0.000 description 1
- 230000005856 abnormality Effects 0.000 description 1
- PBCJIPOGFJYBJE-UHFFFAOYSA-N acetonitrile;hydrate Chemical compound O.CC#N PBCJIPOGFJYBJE-UHFFFAOYSA-N 0.000 description 1
- 231100000215 acute (single dose) toxicity testing Toxicity 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 238000011047 acute toxicity test Methods 0.000 description 1
- 238000007792 addition Methods 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 238000000540 analysis of variance Methods 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 229940125717 barbiturate Drugs 0.000 description 1
- HNYOPLTXPVRDBG-UHFFFAOYSA-N barbituric acid Chemical compound O=C1CC(=O)NC(=O)N1 HNYOPLTXPVRDBG-UHFFFAOYSA-N 0.000 description 1
- 229940049706 benzodiazepine Drugs 0.000 description 1
- 150000001557 benzodiazepines Chemical class 0.000 description 1
- 235000019658 bitter taste Nutrition 0.000 description 1
- 210000003169 central nervous system Anatomy 0.000 description 1
- 208000026106 cerebrovascular disease Diseases 0.000 description 1
- 238000002144 chemical decomposition reaction Methods 0.000 description 1
- 208000023652 chronic gastritis Diseases 0.000 description 1
- 231100000132 chronic toxicity testing Toxicity 0.000 description 1
- 238000004140 cleaning Methods 0.000 description 1
- 230000035602 clotting Effects 0.000 description 1
- 235000009508 confectionery Nutrition 0.000 description 1
- 230000001276 controlling effect Effects 0.000 description 1
- 208000029078 coronary artery disease Diseases 0.000 description 1
- 230000002596 correlated effect Effects 0.000 description 1
- 238000005520 cutting process Methods 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 235000019425 dextrin Nutrition 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 238000002405 diagnostic procedure Methods 0.000 description 1
- 238000006073 displacement reaction Methods 0.000 description 1
- 230000005059 dormancy Effects 0.000 description 1
- 206010013663 drug dependence Diseases 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 230000002526 effect on cardiovascular system Effects 0.000 description 1
- 230000000517 effect on sleep Effects 0.000 description 1
- 230000005611 electricity Effects 0.000 description 1
- 238000000556 factor analysis Methods 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 235000019634 flavors Nutrition 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 235000008434 ginseng Nutrition 0.000 description 1
- 230000037308 hair color Effects 0.000 description 1
- 230000002489 hematologic effect Effects 0.000 description 1
- 230000002008 hemorrhagic effect Effects 0.000 description 1
- 208000006454 hepatitis Diseases 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 238000007689 inspection Methods 0.000 description 1
- 201000005851 intracranial arteriosclerosis Diseases 0.000 description 1
- 208000019423 liver disease Diseases 0.000 description 1
- 231100001252 long-term toxicity Toxicity 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 238000002483 medication Methods 0.000 description 1
- 230000009245 menopause Effects 0.000 description 1
- 230000003340 mental effect Effects 0.000 description 1
- JWHHANVGNNWIRI-UHFFFAOYSA-N methanol phosphoric acid hydrate Chemical compound O.OC.OP(O)(O)=O JWHHANVGNNWIRI-UHFFFAOYSA-N 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 230000003183 myoelectrical effect Effects 0.000 description 1
- 238000003305 oral gavage Methods 0.000 description 1
- 230000000803 paradoxical effect Effects 0.000 description 1
- 230000008506 pathogenesis Effects 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 230000002085 persistent effect Effects 0.000 description 1
- 230000005180 public health Effects 0.000 description 1
- 230000002685 pulmonary effect Effects 0.000 description 1
- 244000132619 red sage Species 0.000 description 1
- 230000028527 righting reflex Effects 0.000 description 1
- 230000036280 sedation Effects 0.000 description 1
- 239000000932 sedative agent Substances 0.000 description 1
- 230000001624 sedative effect Effects 0.000 description 1
- 238000004062 sedimentation Methods 0.000 description 1
- 210000000952 spleen Anatomy 0.000 description 1
- 238000007619 statistical method Methods 0.000 description 1
- 238000012109 statistical procedure Methods 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 238000005728 strengthening Methods 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 208000011117 substance-related disease Diseases 0.000 description 1
- 210000001550 testis Anatomy 0.000 description 1
- 230000002992 thymic effect Effects 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 230000002110 toxicologic effect Effects 0.000 description 1
- 231100000027 toxicology Toxicity 0.000 description 1
- 230000002936 tranquilizing effect Effects 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 238000013519 translation Methods 0.000 description 1
- 238000007492 two-way ANOVA Methods 0.000 description 1
- 208000019206 urinary tract infection Diseases 0.000 description 1
- 210000001835 viscera Anatomy 0.000 description 1
- 230000002747 voluntary effect Effects 0.000 description 1
Landscapes
- Medicines Containing Plant Substances (AREA)
Abstract
Description
组别 | 平均活动次数(10min) | ||||
用药前 | 用药后 | ||||
0-10 | 5-15 | 15-25 | 25-35 | 35-45 | |
水 | 1728.7±200.1 | 1060.7±418.4 | 963±578.7 | 951.9±453.3 | 908.6±507.2 |
参组 | 1564.7±282.2 | 575.7±300.4** | 795.3±456 | 798.3±319.5 | 658.3±380.1 |
落花生枝叶组 | 1692.3±404.9 | 792.5±400.1* | 848.9±480.6 | 903.8±448.7 | 890.9±683.7 |
花丹安神合剂组 | 1499.2±246.1 | 490.3±297.6** | 432.4±290.6** | 394.1±174.2** | 275.8±244.7** |
组别 | 平均活动次数(10min) | ||||
用药前 | 用药后 | ||||
0-10 | 5-15 | 15-25 | 25-35 | 35-45 | |
丹参组 | 1564.7±282.2 | 575.7±300.4 | 795.3±456 | 798.3±319.5 | 658.3±380.1 |
落花生枝叶组 | 1692.3±404.9 | 792.5±400.1 | 848.9±480.6 | 903.8±448.7 | 890.9±683.7 |
花丹安神合剂组 | 1499.2±246.1 | 490.3±-297.6○ | 432.4±290.6▲○ | 394.1±174.2▲○○ | 275.8±244.7▲○○ |
失眠程度 | 例数 | 疗 效 评 价 | |||||
临床痊愈 | 显效 | 有效 | 无效 | 总有效(%) | |||
轻度 | 7 | 1 | 0 | 3 | 3 | 4 | 57.1 |
中度 | 11 | 2 | 1 | 6 | 2 | 9 | 81.82 |
重度 | 12 | 2 | 8 | 1 | 1 | 11 | 91.67 |
总计 | 30 | 5 | 9 | 10 | 6 | 24 | 80.0 |
证型 | 例数 | 疗 效 评 价 | |||||
临床痊愈 | 显效 | 有效 | 无效 | 总有效(%) | |||
肝阳上亢 | 9 | 1 | 1 | 5 | 2 | 7 | 77.78 |
肝郁瘀阻 | 12 | 4 | 5 | 2 | 1 | 11 | 91.67 |
肝郁犯胃 | 1 | 1 | 1 | 100.00 | |||
肝郁犯心 | 1 | 1 | 1 | 100.00 | |||
肝亢肾虚 | 7 | 2 | 2 | 3 | 4 | 57.14 | |
总计 | 30 | 5 | 9 | 10 | 6 | 24 | 80.00 |
Claims (6)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN 200410016412 CN1282463C (zh) | 2004-02-18 | 2004-02-18 | 一种具有平肝活血安神作用的中药组合物、制备方法和应用 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN 200410016412 CN1282463C (zh) | 2004-02-18 | 2004-02-18 | 一种具有平肝活血安神作用的中药组合物、制备方法和应用 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN1657070A CN1657070A (zh) | 2005-08-24 |
CN1282463C true CN1282463C (zh) | 2006-11-01 |
Family
ID=35006900
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN 200410016412 Expired - Lifetime CN1282463C (zh) | 2004-02-18 | 2004-02-18 | 一种具有平肝活血安神作用的中药组合物、制备方法和应用 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN1282463C (zh) |
Families Citing this family (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN108186713A (zh) * | 2018-03-20 | 2018-06-22 | 上海市中医医院 | 一种落花安神口服液及其制备方法和应用 |
CN108403760A (zh) * | 2018-06-07 | 2018-08-17 | 上海凯宝药业股份有限公司 | 一种复方安神中药口服液的制备方法 |
CN115364164B (zh) * | 2022-07-13 | 2023-07-21 | 上海市中医医院 | 一种治疗肝郁型失眠的中药组合物及其应用 |
-
2004
- 2004-02-18 CN CN 200410016412 patent/CN1282463C/zh not_active Expired - Lifetime
Also Published As
Publication number | Publication date |
---|---|
CN1657070A (zh) | 2005-08-24 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN101032560A (zh) | 一种治疗睡眠障碍的中药组合物及制备方法 | |
CN1233387C (zh) | 一种治疗失眠症的中药复方制剂及其制备方法 | |
CN1840044A (zh) | 治疗失眠的药物及其制备方法 | |
CN1824185A (zh) | 一种治疗失眠、功能性消化不良和便秘的中药组合物及其制备方法 | |
CN1282463C (zh) | 一种具有平肝活血安神作用的中药组合物、制备方法和应用 | |
CN1927331A (zh) | 一种治疗慢性心力衰竭的中药制剂 | |
CN1899325A (zh) | 一种治疗小儿腹泻的颗粒剂 | |
CN102861299A (zh) | 一种治疗抑郁症的药物组合物及其制备方法和用途 | |
CN1299734C (zh) | 一种治疗大肠湿热证的中药组合物及其制备方法 | |
CN100339092C (zh) | 一种用于治疗中风的中药组合物及其制备方法和其用途 | |
CN1270762C (zh) | 一种止咳平喘的药物及其制备方法 | |
CN1872186A (zh) | 复方枣仁胶囊及其制备方法 | |
CN1526440A (zh) | 治疗肌肉萎缩肌无力-痿症的中药复方制剂及制备方法 | |
CN1660259A (zh) | 一种治疗肠易激综合征的中药及其制备方法 | |
CN1650895A (zh) | 从天然植物复方制剂中提取增强记忆制品药物的方法 | |
CN1240424C (zh) | 一种治疗血管性痴呆的中药及其制备方法 | |
CN1222305C (zh) | 治疗肝肾不足、气阴亏虚的中药及其制备方法 | |
CN104435298A (zh) | 一种抗抑郁药物组合物 | |
CN1947767A (zh) | 一种治疗及预防小儿智力低下药物及其制备方法 | |
CN1235841C (zh) | 花生叶提取物的制备方法 | |
CN1679691A (zh) | 一种治疗脑萎缩的药物及其制备方法 | |
CN1209158C (zh) | 一种治疗小儿病毒性肺炎的清肺口服液制剂及其制备方法 | |
CN1277574C (zh) | 治疗更年期综合征及美容的组合物、制备方法及其用途 | |
CN1253188C (zh) | 一种治疗高血压的药物及其制备方法 | |
CN1239170C (zh) | 一种用于治疗肝癌的中成药 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
ASS | Succession or assignment of patent right |
Owner name: SHANGAHI KAIBAO PHARMACEUTICAL CO., LTD. Free format text: FORMER OWNER: SHANGHAI TAIWEI INSUSTRIAL CO., LTD. Effective date: 20140121 |
|
C41 | Transfer of patent application or patent right or utility model | ||
COR | Change of bibliographic data |
Free format text: CORRECT: ADDRESS; FROM: 201103 XUHUI, SHANGHAI TO: 201401 FENGXIAN, SHANGHAI |
|
TR01 | Transfer of patent right |
Effective date of registration: 20140121 Address after: 201401 Shanghai City, Fengxian District Shanghai Comprehensive Industrial Development Zone No. 88 Pu Lu Cheng Patentee after: SHANGHAI KAIBAO PHARMACEUTICAL Co.,Ltd. Address before: 201103 in the western suburbs of Shanghai Hongjing road three Cypress Village No. 92 Patentee before: Shanghai Taiwei Insustrial Co.,Ltd. |
|
TR01 | Transfer of patent right |
Effective date of registration: 20220527 Address after: 453000 No. 399, Qinglong Road, Xinxiang Economic Development Zone, Henan Province Patentee after: SHANGHAI KAIBAO XINYI (XINXIANG) PHARMACEUTICAL Co.,Ltd. Address before: 201401 No. 88, Chengpu Road, Shanghai Industrial Comprehensive Development Zone, Fengxian District, Shanghai Patentee before: SHANGHAI KAIBAO PHARMACEUTICAL Co.,Ltd. |
|
TR01 | Transfer of patent right | ||
CX01 | Expiry of patent term |
Granted publication date: 20061101 |
|
CX01 | Expiry of patent term |